Cite
Abstract 647: TTAC-0001, anti-VEGFR2/KDR monoclonal antibody, inhibits VEGFR signaling and tumor growth in preclinical models
MLA
Sung-Woo Kim, et al. “Abstract 647: TTAC-0001, Anti-VEGFR2/KDR Monoclonal Antibody, Inhibits VEGFR Signaling and Tumor Growth in Preclinical Models.” Cancer Research, vol. 71, Apr. 2011, p. 647. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........13ae702369d3b228a822de07494b528b&authtype=sso&custid=ns315887.
APA
Sung-Woo Kim, Yeon Joo Kim, Do-Hyun Nam, Jin-San Yoo, Sang Hoon Lee, Sang Ryeol Shim, Weon Sup Lee, Juyoun Jin, Younggeon Jin, Minjae Park, Heekyoung Yang, & Ho Jun Seol. (2011). Abstract 647: TTAC-0001, anti-VEGFR2/KDR monoclonal antibody, inhibits VEGFR signaling and tumor growth in preclinical models. Cancer Research, 71, 647.
Chicago
Sung-Woo Kim, Yeon Joo Kim, Do-Hyun Nam, Jin-San Yoo, Sang Hoon Lee, Sang Ryeol Shim, Weon Sup Lee, et al. 2011. “Abstract 647: TTAC-0001, Anti-VEGFR2/KDR Monoclonal Antibody, Inhibits VEGFR Signaling and Tumor Growth in Preclinical Models.” Cancer Research 71 (April): 647. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........13ae702369d3b228a822de07494b528b&authtype=sso&custid=ns315887.